Evolocumab is an investigational fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver's ability to remove LDL-C from the blood. 2 The YUKAWA-2 trial evaluated safety, ... Morningstar.com, 2 days ago
Regeneron and Sanofi to Present Results from Four Phase 3 Alirocumab Trials in Hot Line Session at ESC Congress 2014 - Wall Street Select, 5 days ago
Late-stage trial finds Amgen's cholesterol-lowering drug effective with statins - MedCity News, 1 day ago
1 images for "kexin"
] Landsea Green Properties (00106) said it made a successful bid jointly with Suzhou Science and Technology City Kexin Cultural and Tourism Development Company Limited for the land use rights of a parcel of land at north of Wuyi Shan Road ...4 Traders, 1 month ago Landsea (00106) & partner win bid for Rmb269m Suzhou site Etnet.com.hk, 1 month ago
Postal staff member Wang Xuegang (R1) delivers the admission notice to Qi Kexin (L2). Professor Liu Heping (L1), dean of the School of Translation and Interpreting of the Beijing Language and Culture University, came to celebrate Qi's enrollment in ...Noodls, 1 month ago
by Na He, Hong Zheng, Pei Li, Yanrui Zhao, Wei Zhang, Fengju Song, Kexin Chen Background Single nucleotide polymorphisms (SNPs) that reside in microRNA target sites may play an important role in breast cancer development and progression. To reveal ...Plosone.org, 1 month ago
Upcoming Conferences Schedule, Clinical Trial Data Release Schedule, Milestone Payment, and Expansion of Partnership - Research Reports on Celgene, Actavis, Regeneron, ISIS and UnitedHealth
/PRNewswire/ -- Today, Analysts Review released its research reports regarding Celgene Corporation ( NASDAQ: CELG ), Actavis plc ( NYSE: ACT ), Regeneron Pharmaceuticals Inc. ( NASDAQ: REGN ), ISIS Pharmaceuticals, Inc. ( NASDAQ: ISIS ) and ...Wall Street Business Network, 1 day ago UNITEDHEALTH : Upcoming Conferences Schedule, Clinical Trial Data Release Schedule, Milestone Payment, and Expansion of Partnership - Research Reports on Celgene, Actavis, Regeneron, ISIS and UnitedHealth 4 Traders, 1 day ago
More from: Reuters, Minyanville...and 22 other sources
Amgen (AMGN: Quote) announced the submission of a Biologics License Application (BLA) to the U.S. FDA for evolocumab seeking approval for the treatment of high cholesterol. The company said its BLA for evolocumab contains data from approximately ...RTTNews.com, 2 days ago Amgen submits BLA for evolocumab to the FDA Center Watch, 1 day ago
News Categories First BLA submission for PCSK9 inhibitor A biologics license application (BLA) has been submitted to the FDA for evolocumab (Amgen), seeking approval for the treatment of high cholesterol. Evolocumab is an investigational fully ...PT Community, 2 days ago ONLINE FIRST New opportunities for cholesterol lowering: focus on PCSK9 inhibitors Peter Sever, Judy Mackay British Journal of Cardiology, 1 month ago
METABOLIC RESEARCH : Reports on Hypercholesterolemia from Research Institute Provide New Insights (LDL Receptor and Pcsk9 Transcripts are Decreased in Liver of...
Reports on Hypercholesterolemia from Research Institute Provide New Insights (LDL Receptor and Pcsk9 Transcripts are Decreased in Liver of Ovariectomized Rats: Eff ects of Exercise Training) By a News Reporter-Staff News Editor at Genomics & ...4 Traders, 2 days ago Global and Chinese Photodiode Industry Report 2014-2019 Individual.com, 1 month ago Research and Markets: Global and Chinese Photodiode Industry Report 2014-2019 TMC Net, 1 month ago RESEARCH AND MARKETS : Global and Chinese Photodiode Industry Report 2014-2019 4 Traders, 1 month ago
Summary Regeneron has just announced a surprise data release on its main pipeline drug over the Labor Day weekend. I speculate that the news will be favorable. The stock is acting well and Regeneron has been doing well operationally. Valuation ...Seeking Alpha, 4 days ago
Swimmers arrive in Pingtan, Fujian province, on Friday after a five-day relay across the Taiwan Straits. Bao Hua / for China Daily Fourteen swimmers from the Chinese mainland and Taiwan braved strong winds and waves to complete a five-day relay ...CHINAdaily, 1 week ago Relay swimmers conquer the treacherous Taiwan Straits Xinhua News Agency, 1 week ago
More from: , CHINAdaily...and 2 other sources
on your WebpageAdd Widget >Get your members hooked!